Table 2.
Distribution of antibiotic treatment according to acquisition group*
| P. aeruginosa acquisition n = 20 (%) | No P. aeruginosa acquisition n = 106 (%) | Total n = 126 (%) | |
|---|---|---|---|
| Antibiotics active against P. aeruginosa | 10 (50) | 57 (54) | 67 (53) |
| Aminosides | 6 (30) | 17 (16) | 23 (18) |
| Ureido/carboxypenicillins | 5 (25) | 19 (18) | 24 (19) |
| Piperacillin-tazobactam | 5 (25) | 12 (11) | 17 (13) |
| Ticarcillin-clavulanic acid | 0 (0) | 7 (7) | 7 (6) |
| Antipseudomonal cephalosporins | 3 (15) | 13 (12) | 16 (13) |
| Ceftazidime | 3 (15) | 6 (6) | 9 (7) |
| Cefepime | 0 (0) | 7 (7) | 7 (6) |
| Carbapenems | 4 (20) | 12 (11) | 16 (13) |
| Fluoroquinolones | 7 (35) | 33 (31) | 40 (32) |
| Others | 1 (5) | 3 (3) | 4 (3) |
| Fosfomycin | 0 (0) | 2 (2) | 2 (2) |
| Colomycin | 1 (5) | 1 (1) | 2 (2) |
| Antibiotics not active against P. aeruginosa | 14 (70) | 85 (80) | 99 (79) |
| Glycopeptides | 5 (25) | 30 (28) | 35 (28) |
| Non-antipseudomonal penicillins | 4 (20) | 43 (41) | 47 (37) |
| Penicillin G | 0 (0) | 1 (1) | 1 (1) |
| Penicillin M | 0 (0) | 2 (2) | 2 (2) |
| Amoxicillin | 1 (5) | 3 (3) | 4 (3) |
| Amoxicillin-clavulanic acid | 3 (15) | 37 (35) | 40 (32) |
| Non-antipseudomonal cephalosporins (cefotaxim; cefuroxim; ceftriaxon) | 10 (50) | 23 (22) | 33 (26) |
| Macrolides | 5 (25) | 12 (11) | 17 (13) |
| Other | 2 (10) | 18 (17) | 20 (16) |
| Pristinamycin | 0 (0) | 3 (3) | 3 (2) |
| Metronidazole | 0 (0) | 10 (9) | 10 (8) |
| Cotrimoxazole | 1 (5) | 1 (1) | 2 (2) |
| Rifampicin | 1 (5) | 4 (4) | 5 (4) |
* The data represent the number of patients who received at least one day of antibiotic of each class (percentage of patients in each group).